Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 143

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 143
---
the “Plan”), as amended to increase the number of shares of Common Stock available for issuance under the Plan and the number of shares that may be issued pursuant to incentive stock options by an additional 2,000,000 shares. Proposal No. 5: The approval of the election of two Class I directors to the Board to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Please mark your votes like this FOR AGAINST ABSTAIN Nominees: A. Michael Byrnes B. Lindsey Rolfe, M.D. Proposal No. 6: The ratification of the appointment of Wolf & Company, P.C., as our independent registered public accounting firm for the 2025 fiscal year. Proposal No. 7: The approval of an adjournment of the annual meeting, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes in favor of Proposal No. 1, 2, 3 or 4. CONTROL NUMBER Signature_________________________________ Signature, if held jointly_________________________________ Date___________2025. Note: Signature should agree with name printed hereon. If shares are held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney. 2025 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 29, 2025. To view the Proxy Statement and to Attend the Annual Meeting, please go to: https://www.cstproxy.com/cero/2025 FOLD HERE DO NOT SEPARATE INSERT IN ENVELOPE PROVIDED PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS CERO THERAPEUTICS HOLDINGS, INC. The undersigned appoints Chris Ehrlich and Andrew Kucharchuk, and each of them, as proxies, each with the power to appoint their substitute, and authorizes each of them to represent and to vote, as designated on the reverse hereof, all of the shares of common stock of CERo Therapeutics Holdings, Inc. (the “Company”) held of record by the undersigned at the close of business on March 31, 2025 at the Annual Meeting of the Company to be held on May 29,